Advances in Development of mRNA-Based Therapeutics


Authors: L. Huang, L. Zhang, W. Li, S. Li, J. Wen, H. Li and Z. Liu

Journal: Current Topics in Microbiology and Immunology

DOI: https://doi.org/10.1007/82_2020_222

Publication - Abstract

July 19, 2020

Other Applications Nucleic Acid Lipid Nanoparticles Polymeric Nanoparticles
Recently, mRNA-based therapeutics have been greatly boosted since the development of novel technologies of both mRNA synthesis and delivery system. Promising results were showed in both preclinical and clinical studies in the field of cancer vaccine, tumor immunotherapy, infectious disease prevention and protein replacement therapy. Recent advancements in clinical trials also encouraged scientists to attempt new applications of mRNA therapy such as gene editing and cell programming. These studies bring mRNA therapeutics closer to real-world application. Herein, we provide an overview of recent advances in mRNA-based therapeutics.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Jul 16, 2016
Molecular Therapy Nucleic Acids

Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.

G. Basha, M. Ordobadi, W.R. Scott, A. Cottle, Y. Liu, H. Wang and P.R. Cullis

siRNA Nucleic Acid Lipid Nanoparticles Skeletal Disorders

Sclerostin is a protein secreted by osteocytes that is encoded by the SOSTgene; it decreases bone formation by reducing osteoblast differentiation through inhibition of the Wnt signaling pathway.

Read More


Publication - Abstract

Oct 08, 2018
Nature Medicine

Systemic Messenger RNA as an Etiological Treatment for Acute Intermittent Porphyria

L. Jiang, P. Berraondo, D. Jericó, A. Fontanellas et al.

Polymeric Nanoparticles Metabolic Disorders Small Molecule Drugs
Acute intermittent porphyria (AIP) results from haploinsufficiency of porphobilinogen deaminase (PBGD), the third enzyme in the heme biosynthesis pathway. Patients with AIP have neurovisceral attacks associated with increased hepatic heme demand. Phenobarbital-challenged mice wit...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up